alankravitz

Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.

Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.

Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.

Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.

Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.

Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.

Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.

Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.

Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.

Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.

Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.

Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.

Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.

Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.

Like Lynn, I am NED after treatment in the phase 2 trial of what was known as MDX-1106. I had a high tumor burden and responded rather quickly. I do not believe that there is enough data available to make any valid comparisons of either the durability of response or response rate in patients with prior Yervoy treatment. They have been excluded from earlier BMY trials. Like Lynn, I can’t wait until tomorrow when the ASCO Abstracts start to be made available.